IGC Pharma, Inc. (FRA:IGS1)
Germany · Delayed Price · Currency is EUR | Market Cap | 27.30M -3.5% |
| Revenue (ttm) | 942.64K -6.5% |
| Net Income | -5.49M |
| EPS | -0.07 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.2580 |
| Previous Close | 0.2560 |
| Day's Range | 0.2580 - 0.2580 |
| 52-Week Range | 0.2060 - 0.3860 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 28, 2026 |
About IGC Pharma
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer’s disease in the United States and Colombia. The company’s lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer’s. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer’s disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare provi... [Read more]
Financial Performance
In fiscal year 2025, IGC Pharma's revenue was $1.27 million, a decrease of -5.50% compared to the previous year's $1.35 million. Losses were -$7.12 million, -45.22% less than in 2024.
Financial numbers in USD Financial StatementsNews
IGC Pharma reports Q2 EPS (3c) vs. (2c) last year
Reports Q2 revenue $265,000 vs. $328,000 last year. “CALMA is now approaching enrollment closure, and our focus is on execution, patient follow-up, data quality, and readiness for topline analysis,” s...
IGC Pharma sees cash runway for 12 months from quarterly report filing date
Cash and cash equivalents were approximately $331,000 as of June 30. During the six months ended June 30, the Company received approximately $1.1M of net proceeds from equity issuances and…
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure
Phase 2 topline readout expected in Q4 2026 following patient follow-up, database lock, and unblinding POTOMAC, MD / ACCESS Newswire / August 17, 2026 / IGC Pharma, Inc. (NYSE American:IGC), a clinica...
IGC Pharma Quarterly report: Q2 2026
IGC Pharma has published its Q2 2026 quarterly earnings report on August 14, 2026.
IGC Pharma strengthens regulatory readiness of Phase 2 CALMA trial
IGC Pharma (IGC) announced that it is strengthening its regulatory, biostatistical, artificial intelligence-enabled data science, and strategic pharmaceutical development capabilities as IGC-AD1, the ...
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout
POTOMAC, MD / ACCESS Newswire / August 11, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing treatments for Alzheimer's disease, t...
IGC Pharma evaluates potential civil remedies following federal jury verdict
IGC Pharma (IGC) is evaluating potential civil remedies following the federal jury verdict in United States v. Andrew Left, No. 2:24-CR-456, in the United States District Court for the Central…
IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign
POTOMAC, MD / ACCESS Newswire / July 29, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, t...
IGC Pharma Slides: Investor presentation
IGC Pharma has posted slides in relation to its latest quarterly earnings report, which was published on July 13, 2026.
IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow
Seven presentations highlight patent-pending agentic automation, speech-based cognitive models, EHR mining, and predictive analytics designed to support Alzheimer's discovery and clinical development ...
IGC Pharma CEO, principal financial officer purchase over $1.15M of stock
IGC Pharma (IGC) announced that CEO Ram Mukunda and Principal Financial Officer Claudia Grimaldi have purchased an aggregate of 4,274,853 shares of IGC common stock directly from the Company at…
IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company
Senior management elects restricted common stock at $0.27 per share in lieu of repayment of amounts owed, including more than $552,362 of personal cash previously advanced to IGC POTOMAC, MD / ACCESS ...
IGC Pharma announced beta version of Agentic Harmonization Assistant
IGC Pharma (IGC) announced the beta version of its proprietary Agentic Harmonization Assistant, an enterprise software platform designed to accelerate the harmonization of fragmented Alzheimer’s and a...
IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow
Patent-Pending Multi-Agent Architecture Targets Fragmented Biomedical Data and Expands Toward Imaging, Omics, and Broader Health-Data Applications Ahead of Planned AAIC 2026 Demonstration in London PO...
IGC Pharma reaches 146-patient enrollment target for Phase 2 Calma trial
IGC Pharma (IGC) announced that its Phase 2 Calma trial evaluating IGC-AD1 for agitation associated with Alzheimer’s dementia has reached the Company’s previously disclosed target enrollment of 146 pa...
IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis
Company Continuing Limited Over-Enrollment Activities to Account for Attrition and Support Robust Modified Intent-to-Treat, End-of-Treatment and Exploratory Analyses POTOMAC, MD / ACCESS Newswire / Ju...
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts
POTOMAC, MD / ACCESS Newswire / June 9, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, to...
IGC Pharma adds Mount Sinai clinical site as CALMA trial advances
IGC Pharma (IGC) announced the addition of the Icahn School of Medicine at Mount Sinai in New York as a clinical site in the Company’s Phase 2 CALMA trial evaluating…
IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis
Approximately 80% of target participants have completed trial participation, strengthening momentum toward database lock and topline analysis POTOMAC, MD / ACCESS Newswire / June 2, 2026 / IGC Pharma,...
IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment
- Continued Advancement of CALMA Phase 2 Trial - POTOMAC, MD / ACCESS Newswire / May 19, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company de...
IGC Pharma to present new Tau-PET biomarker research at Global Tau conference
IGC Pharma (IGC) announced that it will present new Tau-PET biomarker research at the 2026 Global Tau Conference, taking place May 14-15, 2026, at the Grand Hyatt Washington in Washington,…
IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference
Research highlights advanced imaging analytics that may support Alzheimer's disease monitoring, patient stratification, and future therapeutic development. POTOMAC, MD / ACCESS Newswire / May 15, 2026...
IGC Pharma Quarterly report: Q1 2026
IGC Pharma has published its Q1 2026 quarterly earnings report on May 15, 2026.
IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase
Outreach initiative supports awareness of agitation and patient engagement as enrollment approaches completion POTOMAC, MD / ACCESS Newswire / April 28, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("I...
IGC adds Kerwin Medical Center as clinical site for Phase 2 CALMA trial
IGC Pharma (IGC) announced the addition of Kerwin Medical Center in Dallas, Texas as a clinical site in the Company’s Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer’s…